| Primary |
| Asthma |
39.6% |
| Drug Use For Unknown Indication |
22.0% |
| Chronic Obstructive Pulmonary Disease |
11.9% |
| Product Used For Unknown Indication |
10.0% |
| Bronchitis |
1.9% |
| Wheezing |
1.9% |
| Condition Aggravated |
1.4% |
| Hypertension |
1.4% |
| Respiratory Tract Infection |
1.2% |
| Cystic Fibrosis |
1.0% |
| Hypereosinophilic Syndrome |
1.0% |
| Renal Osteodystrophy |
1.0% |
| Asthmatic Crisis |
0.7% |
| Cardiac Failure |
0.7% |
| Depression |
0.7% |
| Drug Abuse |
0.7% |
| Infection Prophylaxis |
0.7% |
| Malaise |
0.7% |
| Status Asthmaticus |
0.7% |
| Toothache |
0.7% |
|
| Metabolic Acidosis |
12.2% |
| Lactic Acidosis |
9.6% |
| Asthma |
8.7% |
| Convulsion |
8.7% |
| Wheezing |
7.8% |
| Tachypnoea |
6.1% |
| Toxicity To Various Agents |
5.2% |
| Chronic Obstructive Pulmonary Disease |
4.3% |
| Drug Ineffective |
4.3% |
| Vomiting |
4.3% |
| Product Quality Issue |
3.5% |
| Tachycardia |
3.5% |
| Tremor |
3.5% |
| Cystitis Haemorrhagic |
2.6% |
| Death |
2.6% |
| Dysphagia |
2.6% |
| Dyspnoea |
2.6% |
| Metabolic Alkalosis |
2.6% |
| Oxygen Saturation Decreased |
2.6% |
| Somnolence |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
32.1% |
| Asthma |
18.9% |
| Drug Abuse |
15.8% |
| Chronic Obstructive Pulmonary Disease |
11.1% |
| Drug Use For Unknown Indication |
10.3% |
| Hypertension |
1.6% |
| Depression |
1.2% |
| Bronchospasm |
1.1% |
| Drug Exposure During Pregnancy |
1.0% |
| Atrial Flutter |
0.8% |
| Wheezing |
0.8% |
| Bronchitis |
0.8% |
| Schizophrenia |
0.8% |
| Dyspnoea |
0.7% |
| Prophylaxis |
0.6% |
| Bronchiolitis |
0.5% |
| Cor Pulmonale |
0.5% |
| Coronary Artery Disease |
0.5% |
| Infection |
0.5% |
| Pain |
0.5% |
|
| Mesothelioma |
8.9% |
| Chronic Obstructive Pulmonary Disease |
8.1% |
| Drug Ineffective |
8.1% |
| Tachycardia |
8.1% |
| Wheezing |
8.1% |
| Metabolic Acidosis |
7.4% |
| Angioedema |
5.2% |
| White Blood Cell Count Increased |
5.2% |
| Pneumonia |
4.4% |
| Tachycardia Foetal |
4.4% |
| Toxic Epidermal Necrolysis |
4.4% |
| Weight Increased |
3.7% |
| Aggression |
3.0% |
| Convulsion |
3.0% |
| Cystitis Haemorrhagic |
3.0% |
| Deafness Bilateral |
3.0% |
| Emphysema |
3.0% |
| Infective Exacerbation Of Chronic Obstructive Airways Disease |
3.0% |
| Nightmare |
3.0% |
| Non-hodgkin's Lymphoma |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.5% |
| Drug Use For Unknown Indication |
23.8% |
| Asthma |
10.7% |
| Chronic Obstructive Pulmonary Disease |
6.1% |
| Hypertension |
4.1% |
| Pain |
3.3% |
| Rheumatoid Arthritis |
3.2% |
| Depression |
2.1% |
| Prophylaxis |
1.6% |
| Diabetes Mellitus |
1.3% |
| Dyspnoea |
1.1% |
| Osteoporosis |
1.1% |
| Smoking Cessation Therapy |
1.1% |
| Constipation |
1.1% |
| Crohn's Disease |
1.1% |
| Hiv Infection |
1.1% |
| Atrial Fibrillation |
1.0% |
| Lower Respiratory Tract Infection |
0.9% |
| Non-small Cell Lung Cancer |
0.9% |
| Premedication |
0.8% |
|
| Vomiting |
15.1% |
| Wheezing |
9.1% |
| Pneumonia |
7.0% |
| Weight Decreased |
6.5% |
| Dyspnoea |
6.2% |
| Asthma |
4.7% |
| Pyrexia |
4.7% |
| Tremor |
4.6% |
| Weight Increased |
4.5% |
| Renal Failure Acute |
4.3% |
| Death |
4.0% |
| White Blood Cell Count Increased |
3.8% |
| Sepsis |
3.5% |
| Somnolence |
3.4% |
| Thrombocytopenia |
3.3% |
| Lower Respiratory Tract Infection |
3.2% |
| Respiratory Failure |
3.2% |
| Rash |
3.1% |
| Urticaria |
3.1% |
| Vision Blurred |
3.1% |
|
| Interacting |
| Hypertension |
46.7% |
| Asthma |
20.0% |
| Copd |
13.3% |
| Copd Exacerbation |
13.3% |
| Brain Cancer Metastatic |
6.7% |
|
| Drug Interaction |
60.0% |
| Hypokalaemia |
20.0% |
| Toxicity To Various Agents |
20.0% |
|
